Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events

Gynecologic Cancer

Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial

J Clin Oncol.

Rutten MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, Naaktgeboren CA, van Gorp T, Ter Brugge HG, Hofhuis W, Schreuder HW, Arts HJ, Zusterzeel PL, Pijnenborg JM, van Haaften M, Fons G, Engelen MJ, Boss EA, Vos MC, Gerestein KG, Schutter EM, Opmeer BC, Spijkerboer AM, Bossuyt PM, Mol BW, Kenter GG, Buist MR

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Gynecologic CancerRadio-Oncology

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Lancet.

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ

doi: 10.1016/

Gynecologic Cancer

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

N Engl J Med.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P

doi: 10.1056/NEJMoa1810858.

Gynecologic Cancer

Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database

JAMA Oncol.

Rauh-Hain JA, Melamed A, Wright A, Gockley A, Clemmer JT, Schorge JO, Del Carmen MG, Keating NL

doi: 10.1001/

Gynecologic Cancer

Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer

Gynecol Oncol.

Kumar A, Langstraat CL, DeJong SR, McGree ME, Bakkum-Gamez JN, Weaver AL, LeBrasseur NK, Cliby WA

doi: 10.1016/j.ygyno.2017.07.126.

Gynecologic Cancer

High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium

Cancer Res.

Peres LC, Mallen AR, Townsend MK, Poole EM, Trabert B, Allen NE, Arslan AA, Dossus L, Fortner RT, Gram IT, Hartge P, Idahl A, Kaaks R, Kvaskoff M, Magiocco A, Merritt MA, Quirós JR, Tjonneland A, Trichopoulou A, Tumino R, van Gils C, Visvanathan K, Wentzensen N, Zeleniuch-Jacquotte A, Tworoger SS

doi: 10.1158/0008-5472.CAN-19-1554.

Gynecologic Cancer

Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery

Gynecol Oncol.

Kranawetter M, Ataseven B, Grimm C, Schneider S, Riss S, Alesina P, Prader S, Walz MK, Harpain F, Stift A, Heitz F, Reinthaller A, Polterauer S, Harter P, du Bois A

doi: 10.1016/j.ygyno.

Breast Cancer

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials

Lancet Oncol.

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R, McCluggage WG, Perren T, Panici PB, Kenter G, Casado A, Mendiola C, Stuart G, Reed NS, Kehoe S; EORTC; MRC CHORUS study investigators

doi: 10.1016/S1470-2045

Related content

Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial

Recent Developments in Metastatic Breast Cancer

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database

Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer

High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium

Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials